Claims for Patent: 6,355,684

Summary for Patent: 6,355,684

Title:	Antimicrobial treatment for herpes simplex virus and other infectious diseases
Abstract:	An improved medical treatment and medicine is provided to quickly and safely resolve herpes and other microbial infections. The inexpensive user-friendly medicine can be applied and maintained on the infected region until the physical symptoms of the disease disappears and the patient is comfortable and has a normal appearance. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent. In the preferred form, the medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution.
Inventor(s):	Squires; Meryl (Elmhurst, IL)
Assignee:	Squires; Meryl J. (Barrington Hills, IL)
Application Number:	08/646,988
Patent Claims:	1. A medical composition for use in treating diseases: substantially greater than 0.01% to about 0.8% by weight aqueous benzalkonium chloride; from about 40% to about 60% by weight Echinacea purpurea, in the absence of Echinacea angustofolia and raw untreated Echinacea; said antimicrobial isolates of Echinacea purpurea being selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes; glucuronic acid; inulini; inuloid; pentadecadiene; polyacetylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronoarabinoxylan, M.sub.r 35 Kd); PSII (an acid rhamnoarbinogalactan, M.sub.r 450 kD); cynarin; 1,5-di-o-caffeoylquinic acid; acid; 2,3-O-di-caffeoyltartaric acid; borneol; bornyl acetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-B-D-glucopyranoside; 3-O-(6-O-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; and carophylenes; and said antimicrobial isolates of Echinacea purpurea cooperating with said aqueous benzalkonium chloride to provide a herpes-treating medicine for treatment of herpes selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, papilloma virus, varicella zoster virus (herpes zoster), and cytomegalovirus. 2. A medical composition for use in treating herpes virus or other infectious diseases: from about 2% to about 90% by weight of an antimicrobial compound consisting only of Echinacea purpurea; and substantially greater than 0.01% to about 0.8% by weight of a quaternary ammonium salt surfactant selected from the group consisting of alkyl dimethylbenzylammonium chloride, benzalkonium bromide, benzalkonium chloride, alkylbenzyldimethylammonium chloride, alkyldimethybenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diaklyldimethylammonium chloride, octyldecyldimethylammonium chloride, laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, diethyldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammonium chloride. 3. A medical composition in accordance with claim 2 with quarternary ammonium salt: said quaternary ammonium salt consists of benzalkonium chloride; and said antimicrobial compound of Echinacea purpurea consists of: echinacen; echinolone, enzymes; glucuronic acid; inulini; inuloid; pentadecadiene; polyacetylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronoarabinoxylan, M.sub.r 35 kD) and PS II (an acide rhamnoarabinogalactan, M.sub.r 450 kD), cynarin (1,5-di-O-caffeoylquinic acid), acid (2,3-O-di-caffeoyltartaric acid; borneol, bornyl acetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-B-D-glucopyranoside; 3-O-(6-O-mabonyl)-B-D-glucopyranoside; russilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; and carophylenes. 4. A medical composition in accordance with claim 2 with a carrier selected from the group consisting of: glycerin, mineral oil, silica, talc, natural resins, synthetic resins, pyrethrum, tale, thiocyannates, phthalates, cottonseed oil, coconut oil, pine oil, vegetable oil, seed oil, nut oil, fish oil, animal oil, corn meal, beeswax, carnauba wax, beta carotene, garlic oil, camphor oil, soluble vitamins, soluble vitamins, soluble minerals, rape seed oil, olive oil, lipsomes, ascorbic acid, primrose oil, pycnogenol, grape seed oil, lanolin, collagen, herbs, aloe vera, bee pollen, royal jelly, chondroitin sulfate, sea vegetables, fatty acids, lecithin, bioflavinoids, grain oil, grain powder, algea, teas, vinegars, acidophilus, cell salts, glandulars amino acids, and psyllium. 5. A medical composition for use in treating herpes virus or other infectious diseases: from about 40% to about 60% by weight of a phytochemical concentrate of antimicrobial isolates of Echinacea purpurea selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes; glucuronic acid; inulini, inuloid; pentadecadiene; polyacetylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronoarabinoxylan, M.sub.r 35 kD); PSII (an acid rhamnoarbinogalactan, M.sub.r 450 kD); cynarin; 1,5-di-O-caffeoylquinic acid; acid; 2,3-O-di-caffeoyltartaric acid; borneol; bornyl acetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-B-D-glucopyranoside; 3-O-(6-O-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; and carophylenes; substantially greater than 0.01% to about 0.8% by weight of a quaternary ammonium salt surfactant selected from the group consisting of alkyl dimethylbenzylammonium chloride, benzalkonium bromide, benzalkonium chloride, alkylbenzyldimethylammonium chloride, alkyldimethybenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, diethyldimethylammonium chloride, dioctyldimethylammonium chloride, diakyldimethylammonium chloride, octyldecyldimethylammonium chloride, laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammonium chloride; and sterile water providing a diluent and carrier for said phytochemical concentrate, and the overall ratio of said sterile water to said phytochemical concentrate of antimicrobial isolates of said Echinacea purpurea and said quaternary ammonium salt surfactant ranges from about 2:1 to about 100:1. 6. A medical composition in accordance with claim 5 wherein said overall ration of sterile water to said phytochemical concentrate of antimicrobial isolates of said Echinacea purpurea and said quaternary ammonium salt surfactant ranges from about 4:1 to about 40:1. 7. A medical composition in accordance with claim 5 wherein said overall ratio of sterile water to said phytochemical concentrate of antimicrobial isolates of said Echinacea purpurea and said quaternary ammonium salt surfactant ranges from about 6:1 to about 20:1. 8. A medical composition in accordance with claim 5 wherein said ammonium salt surfactant is benzalkonium chloride and the surfactant ratio of said sterile water to said benzalkonium chloride ranges from about 30,000:1 to about 250:1. 9. A medical composition in accordance with claim 8 wherein said surfactant ratio of sterile water to said benzalkonium chloride ranges from about 5000:1 to about 750:1. 10. A medical composition in accordance with claim 5 wherein said antimicrobial isolates of said Echinacea purpurea in said phytochemical concentrate are: from about 0.3% to about 9% by weight echinacoside; from about 0.1% to about 7% by weight PSI (4-O-methyglucoronoarabinoxylan, M.sub.r 35 kD) and PSII (acid rhamnoarabinogalactan, M.sub.r 450 kD); from about 0.1% to about 10% by weight cynarin (1,5-di-O-caffeoylquinic acid) and chicoric acid (2,3-O-di-caffeoyltartaric acid); from about 0.2% to about 4% by weight echinolone; from about 0.2% to about 8% by weight echinacin B; from about 0.1% to about 6% by weight echinaceine; from about 2% to about 7% by weight anthonocyanins comprising cyanidin 3-O-B-D-glucopyranoside and 3-O-(6-O-malonyl-B-D-glucopyranoside); from about 0.01% to about 0.06% by weight pyrrolizidine alkaloids comprising tussilagine an isotussilagine; from about 0.003% to about 0.009% by weight isomeric dodeca isobutylamides and tetroenoic acid; and from about 0.01% to about 2% by weight carophylenes. 11. A method for use in treating diseases: inhibiting microbial infections from microbe-causing diseases by applying a composition of about 2% to about 90% by weight Echinacea purpurea providing viral microbe inhibitors and from substantially greater than 0.01% to about 0.8% by weight of a surfactant on a microbial infected region; and maintaining said composition comprising said Echinacea purpurea providing said microbe inhibitors and said surfactant on said infected region until external symptoms and physical manifestations of the infection substantially disappear about the infected region; said microbe causing-diseases comprising a viral disease selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, papilloma virus, varicella zoster virus (herpes zoster), and cytomegalovirus; said microbe inhibitors are applied to said microbial infected region in the absence of Echinacea angustofolia and raw untreated Echinacea; and said surfactant is a quaternary ammonium salt surfactant selected from the group consisting of alkyl dimethylbenzylammonium chloride, benzalkonium bromide, benzalkonium chloride, alkylbenzyldimethylammonium chloride, alkyldimethybenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diakyldimethylammonium chloride, octyldecyldimethylammonium chloride, laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, diethyldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammonium chloride. 12. A method in accordance with claim 11 wherein: said composition of about 2% to about 20% by weight Echinacea purpurea providing said viral microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant are applied on an external portion of an animal selected from the group consisting of a dog, cat, bird, horse, cow, sheep, swine, farm animal and rodent; and said composition of about 2% to about 20% by weight Echinacea purpurea providing said viral microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant are applied by directly contacting said infected region of said animal with said composition of about 2% to about 20% by weight Echinacea purpurea providing said viral microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant. 13. A method in accordance with claim 11 wherein: said composition of about 2% to about 90% by weight Echinacea purpurea providing said viral microbe inhibitors and from substantially more than 0.01% to about 0.8% to by weight of said surfactant and said quaternary ammonium salt surfactant are applied and maintained on an infected region of a homo sapien until the external appearance of an eruption and outbreak of said infection subside; and said composition of about 2% to about 90% by weight Echinacea purpurea providing said viral microbe inhibitors are selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes; glucuronic acid; inulini; inuloid; pentadecadiene; polyacetylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronoarabinoxylan, M.sub.r 35 Kd); PSII (an acid rhamnoarbinogalactan, M.sub.r 450 kD); cynarin; 1,5-di-o-caffeoylquinic acid; chicoric acid; 2,3-O-di-caffeoyltartaric acid; borneol; borneol acetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-B-D-glucopyranoside; 3-O-(6-O-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine; isometric dodeca isobutylamide; tetraenoic acid; and carophylenes. 14. A method in accordance with claim 11 wherein: said composition of about 2% to about 90% by weight Echinacea purpurea providing said viral microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant are applied simultaneously on the infected region with said surfactant and a carrier; said carrier is selected from the group consisting of an aqueous carrier, water, glycerin, mineral oil, silica, talc, natural resins, synthetic resins, pyrethrum, tale, thiocyannates, phthalates, cottonseed oil, coconut oil, pine oil, vegetable oil, seed oil, nut oil, fish oil, animal oil, alcohol, corn meal, beeswax, carnauba wax, beta carotene, garlic oil, camphor oil, soluble vitamins, soluble minerals, rape seed oil, olive oil, lipsomes, ascorbic acid, primrose oil, pycnogenol, grape seed oil, lanolin, collagen, herbs, aloe vera, bee pollen, royal jelly, chondroitin sulfate, sea vegetables, fatty acids, lecithin, bioflavinoids, grain oil, grain powder, algae, teas, vinegars, acidophilus, cell salts, glandulars, amino acids, psyllium, and a sterile carrier. 15. A method for use in treating herpes virus or other infectious diseases: substantially resolving the physical symptoms of an infected area of a person having an infectious outbreak of herpes simplex virus or other infectious microbial diseases within about 1 hour to about 30 hours by topically applying an antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant to the infected area of said herpes simplex virus or said other infectious microbial disease; and maintaining said antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant on said infected area for about 1 hours to about 30 hours; said 40% to about 60% by weight Echinacea purpurea selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes; glucuronic acid; inulin; inuloid; pentadecadiene; polyacetylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronoarabinoxylan, M.sub.r 35 Kd); PSII (an acid rhamnoarbinogalactan, M.sub.r 450 kD); cynarin; 1,5-di-o-caffeoylquinic acid; chicoric acid; 2,3-O-di-caffeoyltartaric acid; borneol; borneol acetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-B-D-glucopyranoside; 3-O-(6-O-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; and carophylenes; said from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant selected from the group consisting of alkyl dimethylbenzylammonium chloride, benzalkonium bromide, benzalkonium chloride, alkylbenzyldimethylammonium chloride, alkyldimethybenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diakyldimethylammonium chloride, octyldecyldimethylammonium chloride, laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, diethyldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammonium chloride; and sterile water providing a diluent and carrier for said phytochemical concentrate of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant, and the overall ratio of said sterile water to said phytochemical concentrate of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant ranges from about 2:1 to about 100:1. 16. A method in accordance with claim 15 wherein: said infected area of said herpes simplex virus is rinsed and dried to remove any soap or residue on the infected area before said antimicrobial compound is applied; and said quaternary ammonium salt surfactant is benzalkonium chloride and the surfactant ratio of said sterile water to said benzalkonium chloride ranges from about 30,000:1 to about 250:1. 17. A method in accordance with claim 15 wherein: said antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant are applied topically to the infected area by a procedure selected from the group consisting of spraying, dabbing, dusting, swabbing, sponging, brushing, pouring, dispensing, covering and coating; and said infected area is selected from the group consisting of oral mucosa, nasal mucosa, vaginal tissue, penile tissue, labial tissue, anal tissue, periacinal tissue, lips, cutaneous tissue, sub-cutaneous tissue, ocular tissue, conjunctive and eyelids. 18. A method in accordance with claim 15 wherein: vesicular eruption of said herpes simplex virus are resolved in about 19 hours to about 24 hours by maintaining said antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant with about 20% to about 60% sterile water on said infected area for about 19 hours to about 24 hours; and said herpes simplex virus comprising herpes simplex virus 1 or herpes simplex virus 2. 19. A composition of about 2% to about 90% by weight of a plant and from substantially more than 0.01% to about 0.08% by weight of a surfactant, characterized in that the plant consists of Echinacea purpurea, and the surfactant consists of benzalkonium chloride, and said Echinacea purpurea cooperates with said benzalkonium chloride to provide a microbe-inhibiting medicine for treating herpes simplex virus 1, herpes simplex virus 2, papilloma virus, varicella zoster virus herpes zoster), and cytomegalovirus. 20. A composition in accordance with claim 19 with about 40% to about 60% by weight Echinacea purpurea.

Details for Patent 6,355,684

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2010-10-11